{
  "id": 10798358,
  "title": "Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.",
  "url": "https://urgent.news/2026/09/29/eli-lilly-stock-barely-moved-following-viking-therapeutics-impressive-10798358",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-29T21:30:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/09/29/eli-lilly-stock-barely-moved-following-viking-ther/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Eli Lilly (NYSE: LLY) dominates the weight loss market, but fierce competition is on the horizon with several anti-obesity medicine launches in the pipeline. One potential challenger is Viking Therapeutics (NASDAQ: VKTX), a drugmaker that recently presented impressive clinical results from a trial of its lead candidate. The study involved around 180 patients who were given either a dose of VK2735 or a placebo. Starting with weekly administration, patients on the drug lost between 16% and 19% of their body weight after 21 weeks. Following this initial phase, participants transitioned to maintenance regimens, taking VK2735 every other week or monthly for an additional 12 weeks.",
  "summary": "Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.",
        "url": "https://urgent.news/2026/09/29/eli-lilly-stock-barely-moved-following-viking-therapeutics-impressive",
        "published": "2026-09-29T21:50:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}